Finding new uses for existing drugs to treat Alzheimer's disease
Official title: Computational drug repurposing for Alzheimer's disease
Funded at Vanderbilt University · NIH-10954714 · Data updated 2026-11-12
This study is looking at how we can use some already approved medications in new ways to help treat Alzheimer's disease, which impacts memory and thinking for many adults, by checking genetic information to find the best options that could make a difference.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | December 1, 2022 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $53,974 |
| NIH project number | 5F30AG080885-03 |
| Project ID | NIH-10954714 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's disease.
✕Less likely to help
Patients with early-stage cognitive impairment or those without a confirmed diagnosis of Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates how existing medications can be repurposed to treat Alzheimer's disease, a condition that severely affects memory and cognition in millions of adults. The approach involves analyzing genetic data to identify drugs that can reverse harmful gene changes associated with Alzheimer's. By using advanced informatics and electronic health records, the researchers aim to validate these drug candidates in real-world clinical settings. This method promises to be faster and more cost-effective than traditional drug development.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for Alzheimer's disease, improving the quality of life for patients.
How similar studies have gone: Previous research has shown promise in drug repurposing for other conditions, indicating potential success for this novel approach in Alzheimer's treatment.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Grabowska, Monika Eliana — Vanderbilt University
- Study coordinator: Grabowska, Monika Eliana
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.